Search results
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks via Yahoo Finance· 14 hours agoTeva also faces competitive pressure for some of its key branded drugs. The orphan drug exclusivity...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 23 hours ago(NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Orphan Drug ...
Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment
Market Watch· 6 days agoBy Dean Seal Candel Therapeutics said regulators have granted orphan-drug designation to its CAN-3110 drug candidate as a treatment for recurrent high-grade...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 1 hour agoLive from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3% PR Newswire SUZHOU, China and ROCKVILLE, Md., June 4, 2024 SUZHOU, China ...
Precigen shares target lifted on phase 2 data for PRGN-2012 By Investing.com
Investing.com· 2 days agoOn Monday, Stifel maintained a positive stance on Precigen Inc. (NASDAQ:PGEN), raising the...
Annexon surges 48% after scheduling update for Guillain-Barré Syndrome drug data
Market Watch· 1 day agoEastern. ANX005 received orphan drug designation and fast track designation from the Food and Drug Administration. ANX005 for Guillain-Barré Syndrome is ...
The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now
InvestorPlace· 5 days agoOne of the best ways to spot opportunities in penny stocks to buy is by following insiders. After...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 2 days agoAccording to the Financial Times, drug developers raised $6 billion in equity capital markets in January, the largest total since February 2021 – a period when biotech stocks hit their all-time ...
Experimental therapy shows promise in pancreatic cancer clinical trial
Medical Xpress· 4 days agoIt acts by inflaming the microenvironment surrounding the tumor and thereby augmenting the activity...
Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
Zacks via Yahoo Finance· 7 days agoCorcept's (CORT) phase III GRACE study, evaluating its lead candidate, relacorilant, for treating...
